Truseltiq
Truseltiq Has FDA Approval Withdrawn for Cholangiocarcinoma
The FDA has announced the final withdrawal of its approval of infigratinib (Truseltiq, QED Therapeutics) for ...
JUNE 24, 2024
FDA Approves Truseltiq for Some Advanced Cholangiocarcinoma Patients
The FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics) for the treatment of adults with ...
JUNE 4, 2021
Load more